Hepatitis Forums

Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on August 20, 2019, 11:16:29 am

Title: FDA Approves New Drug for Liver Cancer
Post by: Hep Editors on August 20, 2019, 11:16:29 am
On May 10, the Food and Drug Administration (FDA) approved the VEGFR2 inhibitor Cyramza (ramucirumab) for people with hepatocellular carcinoma (HCC) who have a high alpha-fetoprotein (AFP) level and who were previously treated with Nexavar (sorafenib).

The approval was based on results from a Phase III clinical trial that showed Cyramza delays disease progression and extends survival for liver cancer patients with high AFP.

For more...
https://www.hepmag.com/article/fda-approves-new-drug-liver-cancer